Oncology Pharma (ONPH) Stock Statistics & Valuation Metrics
Total Valuation
Oncology Pharma has a market cap or net worth of $1.10M. The enterprise value is $2.58T.
- Market Cap
- $1.10M
- Enterprise Value
- $2.58T
Share Statistics
Oncology Pharma has 27,388,216 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 27,388,216
- Owned by Insiders
- ―
- Owned by Institutions
- <0.01%
Financial Efficiency
Oncology Pharma’s return on equity (ROE) is -83.90 and return on invested capital (ROIC) is -3.25%.
- Return on Equity (ROE)
- -83.90
- Return on Assets (ROA)
- -49.29
- Return on Invested Capital (ROIC)
- -3.25%
- Return on Capital Employed (ROCE)
- -0.05
- Revenue Per Employee
- 0
- Profits Per Employee
- -104.63M
- Employee Count
- 1
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Oncology Pharma is -564.71. Oncology Pharma’s PEG ratio is -5.65.
- PE Ratio
- -564.71
- PS Ratio
- 0.00
- PB Ratio
- 2.64
- Price to FCF
- 2.97
- Price to Operating Cash Flow
- 8.92
- PEG Ratio
- -5.65
Income Statement
In the last 12 months, Oncology Pharma had revenue of 0 and earned -104.63M in profits. Earnings per share was -3.42.
- Revenue
- 0
- Gross Profit
- 0
- Operating Income
- -62.05K
- Pretax Income
- -104.63M
- Net Income
- -104.63M
- EBITDA
- 228.68K
- Earnings Per Share (EPS)
- -3.42
Cash Flow
In the last 12 months, operating cash flow was 11.63K and capital expenditures 0, giving a free cash flow of 11.63K billion.
- Operating Cash Flow
- 11.63K
- Free Cash Flow
- 11.63K
- Free Cash Flow per Share
- 0.00
Dividends & Yields
Oncology Pharma pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- 33.65%
- Earnings Yield
- -0.18%
Stock Price Statistics
- Beta
- -255.85
- 52-Week Price Change
- -33.33%
- 50-Day Moving Average
- 0.05
- 200-Day Moving Average
- 0.06
- Relative Strength Index (RSI)
- 47.79
- Average Volume (3m)
- 15.76K
Financial Position
Oncology Pharma as a current ratio of 0.00, with Debt / Equity ratio of 53.09%
- Current Ratio
- 0.00
- Quick Ratio
- 0.00
- Debt to Market Cap
- 0.01
- Net Debt to EBITDA
- 2.88
- Interest Coverage Ratio
- -0.00
Taxes
In the past 12 months, Oncology Pharma has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Oncology Pharma EV to EBITDA ratio is -301.31, with an EV/FCF ratio of 4.76.
- EV to Sales
- 0.00
- EV to EBITDA
- -301.31
- EV to Free Cash Flow
- 4.76
- EV to Operating Cash Flow
- 4.76
Balance Sheet
Oncology Pharma has $398.00 in cash and marketable securities with $777.62K in debt, giving a net cash position of -$777.22K billion.
- Cash & Marketable Securities
- $398.00
- Total Debt
- $777.62K
- Net Cash
- -$777.22K
- Net Cash Per Share
- -$0.03
- Tangible Book Value Per Share
- $0.03
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Pretax Margin
- 0.00%
- Net Profit Margin
- 0.00%
- EBITDA Margin
- 0.00%
- EBIT Margin
- 0.00%
Analyst Forecast
The average price target for Oncology Pharma is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- 0
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- ―
